DRL launches Pramipexole dihydrochloride extended-release tablets in US

The tablets are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30

Dr Reddy’s Laboratories (DRL) has launched Pramipexole dihydrochloride extended-release tablets 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg, a therapeutic equivalent generic version of Mirapex ER (pramipexole dihydrochloride) extended-release tablets in the US market, following the approval by the United States Food & Drug Administration (US FDA).

The Mirapex ER brand and generic had US sales of approximately $48.3 million MAT for the most recent twelve months ending in June 2015 according to IMS Health.

DRL’s Pramipexole dihydrochloride extended-release tablets mg are available in 0.375 mg, 0.75 mg, 1.5 mg, 3 mg and 4.5 mg in bottle count sizes of 30.